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INTRODUCTION
 The prevalence and clinical presentation 
of Primary Hyperparathyroidism (PHPT) is 
strikingly different among populations.1-4 The 
difference is even more pronounced between 
the West and the East. With the introduction 
of routine calcium screening in the Western 
world, the phenotype there has largely shifted 
from symptomatic to asymptomatic and being 
detected at early stages.5 Contrary to this, in the 
developing countries, where there is no routine 
screening of calcium, PHPT continues to present 
as a symptomatic disease.6-9 Data from the 
Rochester Epidemiological Project reported the 
incidence of PHPT as 21.6 cases per 100000 person 
years.1 There are very few studies regarding 
PHPT in Pakistan and the exact prevalence in not 
known.8-10 This study was designed to analyze 
the clinical presentation, complications, and 
management outcomes in patients with PHPT 
in order to have a better understanding of the 
disease spectrum in Pakistan.
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ABSTRACT
Objective: To study the clinical, biochemical and radiological features and management outcomes of 
patients with primary hyperparathyroidism.
Methods: This retrospective study was conducted at the Aga Khan University Hospital, Karachi, Pakistan 
and comprised data of patients with primary hyperparathyroidism from 2008 to 2017.
Results: Out of 103 patients, 83(80.6%) were female. Overall mean age was 59.3±16.2 years. Musculoskeletal 
manifestations were seen in 60(58.3%) patients and renal manifestations in 28(27.2%). Ostieits fibrosa 
cystica was found in 04(3.88%) patients. Overall, Ultrasound neck and sestamibi scan localized the lesion 
in 66 (64.1%) and 77 (76.2%) patients respectively. Among 79 patients who underwent surgery, 67 (84.8%) 
patients had an adenoma, 05 (6.3%) had hyperplasia and 02(2.53%) patients had parathyroid carcinoma 
whereas histopathology was inconclusive in 5 (6.32%) out of the 79 surgically treated patients. Disease 
recurrence was seen in 13 out of 79(16.45%) patients who underwent surgery.
Conclusion: Primary hyperparathyroidism is associated with significant morbidity in our population. 
Targeted measures like improving patient awareness, routine calcium screening, vitamin D supplementation 
and a high index of suspicion by the clinician may help in early diagnosis of the condition and thus reduce 
morbidity.
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METHODS
 This retrospective study was done after EC/
IRB approval (2019-0850-2587, Dated: 9 February 
2019) at the Aga Khan University Hospital, a 
tertiary Care Centre in Pakistan. This hospital is 
located in Karachi and mainly caters to an urban 
population. Data was collected from the medical 
records of patients with PHPT from January 
2008 to December 2017. This included patient 
demographics, clinical presentation, laboratory 
parameters such as Serum PTH and calcium at 
presentation and on follow up after treatment, 
serum phosphate, vitamin D, albumin, imaging, 
treatment opted and histology. All calcium 
values were corrected for respective albumin 
concentrations. Diagnosis of PHPT was made on 
the basis of hypercalcemia or normocalcemia with 
high or inappropriately normal serum PTH levels. 
All patients aged 18 years and above with PHPT 
were included. Patients with renal failure and 
hypercalcemia due to malignancy were excluded. 
 All clinical and radiological features and 
management outcome of patients were reported 
as frequency and percentages while biochemical 
parameters were reported as mean with 
Standard deviation (depending on the normality 
assumption) or Median with Interquartile range (if 
normality assumption was not met). Stata version 
12 was used for analysis.
RESULTS
	 A	total	of	103	patients	were	identified	with	PHPT	
from 1st Jan, 2008 till 31st Dec, 2017 with mean age 
of 59.3±16.2 years. Majority of the patients were 
female [83 (80.6%)]. Patients presented with various 
clinical manifestations such as 60(58.3%) with 
muscle and/or bone pain, 32(31.1%) with abdominal 
pain and 28(27.2%) with renal manifestations. 
Fragility	 fractures	 leading	 to	difficulty	 in	mobility	
were seen in 13(12.6%) patients. Overall, 26(25%) 
patients suffered with depression and headache in 
23(22.3%) of patients (Fig.1). Total 40(39%) patients 
had their DXA scan done out of which 31(30%) had 
osteoporosis and 06 (5.8%) had osteopenia. Vitamin 
D	deficiency	was	found	in	69(67%)	patients.	Ostieits	
fibrosa	cystica	was	found	in	04	(3.9%)	patients.	None	
of the patients had associated Multiple Endocrine 
Neoplasia	(MEN)	syndrome.
 Majority of the patients 79(76.7%) underwent 
surgical treatment whereas, one fourth of patients 
opted for medical treatment. Histology revealed 
that 67(85%) out of those 79 patients had a 
parathyroid adenoma, whereas hyperplasia was 
seen in 05(6%) and carcinoma in 02(3%) patients. 
Histology was not conclusive in 05(6%) out of the 
79 patients who underwent surgery (refer to Fig.2). 
On kidney ultrasound, 30 (29.1%) patients had renal 
calculi and 01(0.98%) patient had nephrocalcinosiss. 
Ultrasound neck and sestamibi scan were able 
to localize the lesion in 66 (64.1%) and 77 (76.2%) 
patients respectively.
 Mean serum calcium levels were improved 
post-surgery from 12.1 ± 1.8 mg/dl to 8.9 ± 0.8 
mg/dl. Similarly, post-surgery PTH levels were 
decreased from 653.6 ± 683.4 pg/ml to 61.1 ± 88.7 
pg/ml (Table-I). Post-operative hypocalcemia 
developed in 7 (8.8%) patients. Disease recurrence 
as manifested by elevation of PTH on follow up 
visit was seen in 13 (16.5%) out of the 79 patients 
who underwent surgery.
Fig.1: Clinical manifestations of patients presenting
with primary hyperparathyroidism.
Fig.2: Histological distribution of patients
with primary hyperparathyroidism.
n = Total number of Patients who underwent surgery.
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DISCUSSION
 The mean age of our patients at time of diagno-
sis was 59.3±16.2  years. Although this age is sig-
nificantly	higher	 from	the	mean	age	 reported	by	
Biyabani8 and Ahsan9 in earlier studies from Paki-
stan and India,4	this	is	comparable	to	the	findings	
of Yeh11 where the mean age of presentation in the 
Asian subgroup was 60.5 years. This may be due 
to the fact that majority of our patients were from 
an urban population of Karachi where nutritional 
status and socioeconomic conditions are gener-
ally better compared to other parts of the country 
therefore skeletal manifestations were probably 
delayed	 in	 this	 cohort.	A	 striking	finding	 in	 this	
study was the unexplained female predominance 
(80.6%). This has also been reported in other stud-
ies4,9,12 but any causal relationship between gender 
and the disease yet remains unknown.
 In this series we have demonstrated that in 
Pakistan PHPT still presents with overt skeletal 
and renal disease. More than half of the patients 
(58.3%) sought medical attention because of some 
form of musculoskeletal complications such as 
bone pain, generalized body aches or proximal 
muscle weakness and 12.6% had a fragility fracture 
by the time of diagnosis. This degree of severity of 
skeletal disease in the Asian population affected 
by PHPT has consistently been observed across 
various studies from the region.13-15 A study from 
India showed that bone pains and painful proximal 
myopathy were the commonest presentation (47%), 
followed by pathological fractures in 23.5% cases.13 
This percentage was even higher in an Iranian study 
where (93.5%) patients suffered from bone pains, 
deformities, pathologic fractures, and localized bone 
tumors.15	Ostietis	fibrosa	cystica	 (OFC),	 the	classic	
form of skeletal complications of PHPT is now 
rarely seen in the developed countries. However, 
OFC still remains a predominant presentation of 
PHPT in this region.7,8,16 In our study, four patients 
(3.8%) had OFC. All of them had a concomitant 
Vitamin	D	deficiency.	This	extent	of	skeletal	disease	
may partly be attributed to coexisting vitamin D 
deficiency	as	long	standing	Vitamin	D	deficiency	can	
further exaggerate the secretion of PTH. Although 
we know that Vitamin D and calcium nutrition 
play a role in determination of severity of skeletal 
disease but It is yet not clear whether the austerity 
of skeletal disease in this region is only because of 
hypovitaminosis D and calcium malnutrition or 
there are any additional pathogenic environmental 
factors or genetic and racial differences playing 
a role. This hypothesis is further supported by a 
Chinese study which compared BMD in patients 
with PHPT in a single Centre from China to that 
of USA and noted lower bone mineral density in 
Chinese population as compared to USA in patients 
with PHPT.14 Same goes for the renal manifestations 
the rate of which is higher in Asian population as 
compared to the West. Ultrasound abdomen was 
done in all patients including those presenting 
with abdominal pain to look for renal calculi and 
nephrocalcinosis. Renal manifestations were found 
in 27.2% of our patients which is comparable to the 
findings	 reported	 in	 studies	 from	 our	 region.4,8-10 
Further research is required to fully understand the 
racial, genetic and environmental factors involved if 
any	and	their	potential	effects	on	the	clinical	profile	
of patients in this part of world. Lipase and amylase 
were checked in 6(5.8%) patients due to suspicion 
of pancreatitis which all turned out to be within 
normal range. Overall, 26 (25%) patients reported 
having a preexisting diagnosis of depression at the 
first	clinic	visit	with	the	endocrinologist.	This	high	
incidence of depression seen in this cohort, however, 
is comparable to the incidence of depression in the 
general population of Pakistan and a cause effect 
relationship with PHPT could not be established. It 
is interesting to note that 22% of the patients were 
asymptomatic at presentation and were referred to 
the	endocrinology	service	upon	 incidental	finding	
of hypercalcemia on their routine health checkup.
Primary Hyperparathyroidism
Table-I: Biochemical parameters of study participants.
 Normal Range Means ± SD Range (Min-Max)
Serum Calcium (mg/dl) (Pre-operative) 8.1 - 10.4 12.1 ± 1.8 8.8 - 18.8
Serum Calcium (mg/dl) (Post-operative) 8.1 - 10.4 8.9 ± 0.8 5.8 - 11.1
Serum PO4 (mg/dl) 2.5 - 4.8 2.4 ± 0.8 1 - 4.5
Serum PTH (pg/ml) (Pre-operative) 16 - 81 653.6 ± 683.4 76 – 2500
Serum PTH (pg/ml) (Post-operative) 16 - 81 61.1 ± 88.7 3 – 575
Serum Creatinine (mg/dl) 0.5 - 1.2 0.8 ± 0.3 0.3 - 1.9
Serum Albumin (g/dl) 3.5 - 5.2 3.8 ± 0.7 2 - 5.2
Vitamin	D3	ng/ml	 Sufficiency>30	 23.4	±	15.1	 4	–	101
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 Normocalcemic	hyperparathyroidism	is	a	newer	
phenotypic variant of PHPT that has evolved 
over the last two decades as a result of the routine 
evaluation of serum biochemistry in the developed 
countries.17,18 Although the dynamics of this entity are 
not fully understood at the moment, various studies 
have shown that it is not an indolent condition and 
patients with normocalcemic hyperparathyroidism 
also have an increased prevalence of bone and 
renal complications.19-21 Although increasingly 
seen in modern day practice, the epidemiology of 
normocalcemic primary hyperparathyroidism is 
not exactly known,. In a population based study 
from Canada, the prevalence was 16.7%.22 In a 
study from Lahore, Pakistan, normocalcaemia was 
seen in 21.88% of patients.10 However, in our series, 
only one patient had normocalcemia. There was 
coexistent	vitamin	D	deficiency	in	this	patient	and	
a history of fragility fracture. It is important to note 
that	Vitamin	D	deficiency	can	cause	calcium	levels	
to fall in the normal range and the normocalcemia 
in	 this	 situation	 may	 not	 accurately	 reflect	 the	
gravity of disease as such patients may become 
hypercalcemic on correction of Vitamin D levels. 
There is also a possibility of missing the diagnosis if 
only the absence of hypercalcemia is used to exclude 
the diagnosis of PHPT. It is prudent for the clinicians 
to understand this interplay of Calcium, Vitamin 
D	and	PTH	and	that	this	may	have	influenced	the	
disease presentation in our region. The clinicians 
should be vigilant to identify and correct Vitamin 
D	 deficiency	 in	 PHPT	 patients	 before	 making	
treatment decisions. It is also important to mention 
here the other end of the paradigm. In the recent 
years a trend has been seen among clinicians 
in Pakistan to empirically prescribe vitamin D 
to patients with musculoskeletal pains without 
documenting	vitamin	D	deficiency.	This	has	led	to	
cases of Vitamin D intoxication and hypercalcemia. 
The situation can be critical if this practice is done 
in a patient of PHPT23 and implies that Vitamin 
D should be checked in all patients suspected of 
having PHPT and prescribed only if needed.
 There is wide variability in the location of 
parathyroid gland and various noninvasive 
techniques have been developed for preoperative 
localization of disease in order to make the 
surgical procedure minimally invasive. The most 
widely used and credible modality is Technetium 
99 sestamibi and has shown high sensitivity for 
pre-operative localization in PHPT.24 Accurate 
localization was done in 76.2% of our patients 
upon	 sestamibi	 scan.	Nonetheless,	Ultrasound	of	
neck was also seen to be an effective localization 
tool as it is cheap and readily available in a cost 
constrained healthcare system and was able to 
localize the lesion in 64.1 % of our patients. Ectopic 
location of parathyroid gland in the mediastinum 
was detected in four cases.
	 Surgical	excision	remains	the	standard	definitive	
treatment for PHPT. All patients were offered 
surgery	as	first	line	treatment,	however,	one	fourth	
of patients refused surgery and opted for medical 
treatment. Majority of our patients underwent 
surgical treatment (76.7%). Excision of the involved 
gland was performed in cases where pre-operative 
localization was achieved whereas bilateral neck 
exploration was performed in the non-localized 
cases. However, recurrence of the disease was 
seen in 13(12.6%) patients. This may partly be 
attributed to the failure to localize the lesion on 
pre-operative imaging in nine patients and ectopic 
location of parathyroid glands in the mediastinum 
in two of them. Median sternotomy was done in 
cases of ectopically located parathyroid gland. 
Hungry bone syndrome occurred in seven of 
our patients post operatively and was managed 
without any complications. The low incidence of 
post-operative hypocalcemia and hungry bone 
syndrome was probably because of the practice in 
our Centre to replete Vitamin D in all patients who 
are	deficient	pre	operatively.	In	the	Western	data,	a	
significant	cases	of	PHPT	are	associated	with	MEN	
syndrome,25 however there is no data from Pakistan 
regarding	PHPT	in	context	of	MEN	syndrome.	To	
the best of our knowledge none of our patients had 
PHPT	 associated	 with	 MEN	 syndrome	 although	
genetic testing was not done. It is imperative to 
screen all patients presenting with PHPT at age 
younger	 than	 40	 years	 for	 MEN	 syndromes	 by	
genetic testing. The fact that genetic testing was 
not done in our patients who were 40 years of age 
or	younger	reflects	the	potential	lack	of	awareness	
among clinicians about possibility of associated 
MEN	syndromes	in	these	patients.	Clinicians	need	
to understand the seriousness of this entity and 
need to be more vigilant not to miss the diagnosis.
Limitation of this study:  It was a single center 
study with small number of patients and most of 
them from an urban population therefore it may 
not	reflect	the	actual	picture	of	the	entire	Pakistani	
population, however it effectively highlights the 
morbidity associated with PHPT in our population. 
 The disease severity may partly appertain to 
the delay in seeking medical care due to illiteracy, 
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lack of awareness and inaccessibility of healthcare 
facilities	in	a	financially	constrained	population	of	
this country. The conundrum if this difference in 
presentation and disease severity from the West 
is only a matter of nutritional and socioeconomic 
differences or there are any other genetic factors 
playing a role remains to be answered. Targeted 
measures like improving patient awareness, routine 
calcium screening, vitamin D supplementation 
and a high index of suspicion by the clinician may 
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